
Exploring a New Oral Option for Alzheimer Treatment With Sonya Miller
In late-2022, TauRx announced positive 12-month findings from its phase 3 LUCIDITY study (NCT03446001) testing hydromethylthionine mesylate (HMTM), an investigational tau aggregation inhibitor, in a diverse patient population ranging from mild cognitively …